NanoViricides reports $3.64 million net cash use for quarter ended Sept. 30, 2026
NNVC•NanoViricides reported $3.64 million in net cash use for the quarter ended Sept. 30, 2026, with about $2.98 million in cash and cash equivalents and $3.1 million in current liabilities. It said funding was insufficient to sustain planned operations through Nov. 16, 2027, though it projected enough funding to complete two Phase II trials of NV-387 oral gummies.
1. Cash and clinical trials
NanoViricides reported approximately $3.64 million in net cash use for the quarter, including nonrecurring research and development expenditures for Phase II clinical trials. At Sept. 30, the company had about $2.98 million in cash and cash equivalents and approximately $3.1 million in current liabilities. NV-387 oral gummies entered separate Phase II trials for Ebola Bundibugyo and mpox, which the company said it had sufficient funding to complete. Management said funding would not sustain operations through Nov. 16, 2027, under planned objectives, and that it would adjust its business plan to available resources.




